Risks and benefits of bisphosphonates

Area of Science:

• Oncology
• Pharmacology
• Bone Metabolism

Background:

• Bone metastases are common in breast and prostate cancers, causing significant morbidity and impacting patient independence.
• Bisphosphonates reduce skeletal morbidity by 30-50% in various cancers, improving quality of life.
• Their use is expanding to prevent treatment-induced bone loss from therapies like aromatase inhibitors and androgen deprivation therapy.

Purpose of the Study:

• To review the role of bisphosphonates in managing bone metastases and preventing treatment-induced bone loss.
• To discuss the efficacy and safety profile of bisphosphonates in cancer patients.
• To highlight emerging concerns such as renal dysfunction and bisphosphonate-associated osteonecrosis of the jaw (ONJ).

Main Methods:

• Literature review on bisphosphonate efficacy and safety in oncology.
• Analysis of bisphosphonate use in preventing skeletal-related events.
• Discussion of adverse events and risk management strategies.

Main Results:

• Bisphosphonates are effective in reducing skeletal morbidity and bone pain in cancer patients.
• They are generally safe and well-tolerated, with mild and infrequent adverse events.
• Potential risks include renal dysfunction and osteonecrosis of the jaw (ONJ).

Conclusions:

• Bisphosphonates are a valuable therapeutic option for managing bone metastases and preventing treatment-induced bone loss in cancer patients.
• The benefits of bisphosphonate therapy generally outweigh the risks.
• Awareness and management strategies for ONJ are crucial for patient safety.